Guidance on the process for ending a clinical trial.
Similar Posts
MHRA approves teplizumab to delay progression of type 1 diabetes
As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.
Decision: Advertising Investigations: August 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Device specific vigilance guidance: Cardiac Implantable Electronic Devices (CIEDs)
Guidance for manufacturers of cardiac implantable electronic devices and their leads. It outlines specific scenarios that should be considered when determining if an incident is reportable.
20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys
People are urged to avoid risky online buys and protect their health, as the MHRA seizes over 4.4 million doses of unlicensed erectile dysfunction medicines in 2025 alone.
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)
Information for patients, public and healthcare professionals.
Strengthening collaboration between the MHRA and the Department of Health Northern Ireland
The MHRA and Northern Ireland partners are working together to support innovation, enhance patient safety and ensure people in Northern Ireland benefit from world-class regulation.